Apotex Gains Canada Approval for Generic Ozempic
Toronto, Canada | May 1, 2026 Apotex has received Health Canada approval for Apo-Semaglutide Injection™, a generic equivalent of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Toronto, Canada | May 1, 2026 Apotex has received Health Canada approval for Apo-Semaglutide Injection™, a generic equivalent of...
CAMBRIDGE, Mass. & HOUSTON, April 9, 2026 Decoy Therapeutics, Inc. is rapidly gaining momentum as it enters a highly...
Vancouver, British Columbia — November 20, 2025 — PreveCeutical Medical Inc. has issued a formal clarification regarding its earlier...
